Entry into precision fermentation through MicroBiopharm Japan's proprietary P450 enzyme library

通过MicroBiopharm Japan专有的P450酶库进入精密发酵领域

India-based Gujarat Themis Biosyn Limited (GTBL) has announced the completion of the acquisition of 100% equity shareholding in MicroBiopharm Japan (MBJ), through Themis Biosyn Japan Limited, a wholly owned subsidiary incorporated in Japan.

总部位于印度的古吉拉特邦Themis Biosyn有限公司（GTBL）宣布，通过其在日本注册成立的全资子公司Themis Biosyn Japan Limited，已完成对MicroBiopharm Japan（MBJ）100%股权的收购。

The transaction, first announced on May 22, 2026, has now been closed following receipt of all customary regulatory approvals and satisfaction of closing conditions.

该交易于2026年5月22日首次宣布，在获得所有常规监管批准并满足交割条件后，现已完成交割。

The acquisition was made from funds managed or advised by T Capital Partners Co., a Japan-based private equity fund, for a total consideration of JPY 21.5 billion, funded through an optimal mix of debt and equity. The transaction is expected to be EPS accretive for GTBL. The existing MBJ management team will continue to lead operations..

此次收购由日本私募股权基金T Capital Partners Co.管理或提供顾问服务的资金完成，总对价为215亿日元，通过债务和股权的最优组合融资。预计该交易将提升GTBL的每股收益（EPS）。现有的MBJ管理团队将继续领导运营。

The acquisition accelerates GTBL's transition towards becoming a fermentation-based, globally integrated CDMO, and is expected to deliver the following key benefits:

此次收购加速了GTBL向基于发酵的全球一体化CDMO的转型，并有望带来以下关键益处：

Precision Fermentation & Enzyme-based bioconversion platforms:

精密发酵与酶基生物转化平台：

Entry into precision fermentation through MBJ's proprietary P450 enzyme library (hydroxylation) and thereby reducing reliance on traditional chemical routes.

通过MBJ专有的P450酶库（羟基化）进入精密发酵领域，从而减少对传统化学路径的依赖。

Proprietary Products – APIs:

专有产品 – API：

Supply of API/Intermediates for Oncology, Immunosuppressants, Peptides and Antibiotics to leading global pharma companies, including Big Pharma, broadening GTBL's product depth and revenue diversification.

向包括大型制药公司在内的全球领先制药企业供应肿瘤学、免疫抑制剂、肽类和抗生素领域的原料药/中间体，从而拓宽GTBL的产品深度并实现收入多元化。

Advanced Biologics & Novel Modalities:

先进生物制品与新型疗法：

Access to Plasmid DNA, ADC conjugation, and recombinant protein technologies, positioning the combined platform in high-growth, innovation-led pharmaceutical segments.

获取质粒DNA、抗体药物偶联物（ADC）偶联以及重组蛋白技术，将整合后的平台定位于高增长、创新驱动的制药领域。

Precision Fermentation:

精密发酵：

Entry into precision fermentation through MBJ's proprietary P450 enzyme library (hydroxylation), complementing GTBL's existing fermentation strengths and reducing reliance on traditional chemical routes.

通过MBJ专有的P450酶库（羟基化）进入精密发酵领域，补充GTBL现有的发酵优势，并减少对传统化学路线的依赖。

Scalable, Regulated Manufacturing Footprint:

可扩展、受监管的生产布局：

Three GMP-compliant sites with strong FDA and PMDA inspection track records, enabling expanded access to regulated global markets and a fully integrated CDMO platform spanning discovery, development and commercial manufacturing.

拥有三个符合GMP标准的生产基地，具备优异的FDA和PMDA检查记录，能够拓展受监管的全球市场准入，并提供一个涵盖发现、开发及商业化生产的全集成CDMO平台。

Diversified Global Revenue Base & Big Pharma Access:

多元化的全球收入基础及大型制药企业准入：

~40% of MBJ's revenues are generated from outside Japan, backed by long-standing relationships with blue-chip pharma customers across Asia, Europe and North America — enabling cross-selling and accelerated market penetration.

MBJ约40%的收入来自日本以外市场，这得益于其与亚洲、欧洲和北美地区的蓝筹制药客户建立的长期合作关系，从而推动了交叉销售并加速了市场渗透。

India Cost Advantage for Margin Expansion:

印度成本优势助力利润率扩张：

Opportunity to leverage GTBL's India manufacturing scale to improve cost competitiveness and drive margin expansion on high-value products.

有机会利用 GTBL 在印度的制造规模优势，提升成本竞争力，并推动高价值产品的利润率扩张。